



June 2017

Dear Healthcare Provider,

The information contained here may be very important to your practice. Please take a moment to review this document.

INDIANA MEDICARE NON-COVERAGE UPDATE

Please see page 2 for information on ABN requirements for genetic testing for thrombophilia.

BLOOD LEAD TESTING: FREQUENTLY ASKED QUESTIONS

1. How is Alverno supporting clinicians with patients affected by the CDC recommendations?

PCL Alverno is gathering data on all lead testing that was performed between June 11, 2014, and May 17, 2017. An attempt will be made to contact individual physicians by mail with a list of patients who may be affected by the CDC recommendations. **However, we cannot guarantee that all patients will be identified, and we encourage you to determine which patients from your practice may need to be retested.**

2. Will repeat testing of lead on children or pregnant/lactating women be done at no charge?

Repeat testing will be charged. Our billing group has stated that insurance does not restrict the number of lead tests performed per year and that repeat testing in the outpatient setting should be covered. If in doubt, patients should check with their insurance plan regarding coverage.

3. How will this FDA Recall affect turnaround time (TAT)?

All Blood Lead testing will be sent to ARUP, which will add 1-2 days to TAT. Since this is a nationwide issue, we expect ARUP will be getting a surge in test requests. This may contribute to a longer than normal TAT.

4. What tubes will be accepted by ARUP?

ARUP has stated Tan (Lead) and Navy Blue (Trace Metal) collection tubes are preferred. Due to the widespread nature of this recall, supplies of the Lead and Trace Metal collection tubes may be limited. ARUP discourages but will accept Lavender EDTA Vacutainer and Microtainer tubes.

Find Us on Facebook, LinkedIn and Google Plus!

2434 Interstate Plaza Drive, Hammond, IN 46324
toll free 800.937.5521 · phone 219.989.3700 · fax 219.989.3900

www.PCLAlverno.com